�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���, �Ͼ�, 210042

��������Ϊ�����������Ӧ����׿���,���������ư߿�״��м������м���ؽ���.������ɵĢ򡢢����ٴ�����֤��,����25 mg��50 mgƤ��ע��,ÿ��2������12��,���߸����ڵ�������������,�������Ը��ƻ��ߵ�֢״����������,������Ӧ��������΢,�������֮�������ͳ��ѧ����,�����ƶ�ͯ�ض���м������Ҳ�кܺ�ǰ��.�������տ���Ϊ���ضȰ߿�״��м������м���ؽ��׻��ߵ�����ѡ��,�������һ���Ĵ��ģ�ٴ������Գ����ȷ�����������.

Institute of Dennatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China

Etanercept, a tumor necrosis factor-a(TNF-a)antagonist, is used for the treatment of plaque psoriasis and psoriatic arthritis. As phase �� and �� clinical trials have proved, short term(25mg or 50 mg subcutaneously twice a week for 12 weeks) or longer etanercept therapy can significantly improve patients' symptoms and quality of life, with few mild adverse events. Also, it has good prospect in the treatment of severe pediatric psoriasis. It has been proven to be a good option for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; however, large-scale clinical trials are needed to thoroughly recognize its characteristics.